Post-Test Novel Newer and Emerging Treatment Options for the Management of Non-MSI-H Metastatic Colorectal Cancer Post-Test Which of the following statements regarding non-MSI mCRC is TRUE? Approximately 65% of patients with mCRC have the non-MSI-H subtype Efficacious immunotherapy with checkpoint inhibitors is limited to patients with non-MSI-H/pMMR tumors Non-MSI-H mCRC has a worse prognosis and higher relapse rate than MSI-H/dMMR CRC Patients with non-MSI-H mCRC are less likely to develop resistance after immunotherapy Recent data has shown that the combination of ______ resulted in a confirmed ORR of 23% and a 12-month OS of 74% in patients with non-MSI-H mCRC. Avelumab and cetuximab Bevacizumab and short-course radiotherapy Botensilimab and balstilimab Nivolumab and pembrolizumab How confident are you now in your ability to identify and manage adverse events and/or treatment resistance in patients with mCRC receiving immunotherapy? Very confident Confident Somewhat confident Not very confident Not at all confident Previous
